AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) insider Justin Noznesky sold 6,182 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
AtriCure Stock Down 1.8%
ATRC stock opened at $40.15 on Friday. The company has a 50 day moving average of $30.91 and a two-hundred day moving average of $31.29. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 191.20 and a beta of 1.24. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $43.18. The company has a quick ratio of 3.18, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.
AtriCure (NASDAQ:ATRC – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts anticipate that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.
Key Headlines Impacting AtriCure
- Positive Sentiment: UBS lowered its price target from $55 to $50 but maintained a Buy rating, implying substantial upside from recent trading levels. The revised target remains supportive of the long-term outlook for AtriCure’s medical-device business. UBS price target report
- Positive Sentiment: AtriCure recently exceeded quarterly expectations, reporting earnings per share of $0.18 versus an analyst estimate of $0.13 and revenue of $153.6 million versus estimates of $151.8 million. Results also improved from a loss in the year-ago period, supporting the company’s growth and profitability narrative. AtriCure earnings report
- Neutral Sentiment: Recent coverage is focused on whether options activity signals an unusually large upcoming move in ATRC. No specific direction is established, but elevated options interest may contribute to short-term volatility. AtriCure options activity article
- Neutral Sentiment: Investors are also reviewing new share-registration filings. Such filings can provide AtriCure with financing flexibility, although the potential for future share issuance may raise dilution concerns. AtriCure share registration article
- Negative Sentiment: Several insiders sold shares: Director Sven Wehrwein reduced his holdings by about 38%, while executives Justin J. Noznesky and Vinayak Doraiswamy cut their positions by approximately 6% each. The sales, totaling roughly $1.42 million, may weigh on sentiment, particularly after ATRC’s strong recent run.
Wall Street Analysts Forecast Growth
ATRC has been the subject of several research reports. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research report on Tuesday, July 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, UBS Group cut their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.
Get Our Latest Stock Report on ATRC
Institutional Investors Weigh In On AtriCure
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. acquired a new position in AtriCure during the second quarter valued at approximately $37,000. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure during the 2nd quarter worth $40,000. Smartleaf Asset Management LLC grew its stake in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares during the last quarter. Fifth Third Bancorp acquired a new position in shares of AtriCure during the first quarter worth approximately $51,000. Finally, Global Retirement Partners LLC bought a new stake in AtriCure in the 4th quarter valued at $73,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.
About AtriCure
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Stories
- Five stocks we like better than AtriCure
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
